» Articles » PMID: 36609566

A Comprehensive Single-cell Map of T Cell Exhaustion-associated Immune Environments in Human Breast Cancer

Overview
Journal Nat Commun
Specialty Biology
Date 2023 Jan 7
PMID 36609566
Authors
Affiliations
Soon will be listed here.
Abstract

Immune checkpoint therapy in breast cancer remains restricted to triple negative patients, and long-term clinical benefit is rare. The primary aim of immune checkpoint blockade is to prevent or reverse exhausted T cell states, but T cell exhaustion in breast tumors is not well understood. Here, we use single-cell transcriptomics combined with imaging mass cytometry to systematically study immune environments of human breast tumors that either do or do not contain exhausted T cells, with a focus on luminal subtypes. We find that the presence of a PD-1 exhaustion-like T cell phenotype is associated with an inflammatory immune environment with a characteristic cytotoxic profile, increased myeloid cell activation, evidence for elevated immunomodulatory, chemotactic, and cytokine signaling, and accumulation of natural killer T cells. Tumors harboring exhausted-like T cells show increased expression of MHC-I on tumor cells and of CXCL13 on T cells, as well as altered spatial organization with more immature rather than mature tertiary lymphoid structures. Our data reveal fundamental differences between immune environments with and without exhausted T cells within luminal breast cancer, and show that expression of PD-1 and CXCL13 on T cells, and MHC-I - but not PD-L1 - on tumor cells are strong distinguishing features between these environments.

Citing Articles

Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer.

Luo L, Yang P, Mastoraki S, Rao X, Wang Y, Kettner N Mol Cancer. 2025; 24(1):48.

PMID: 39955556 PMC: 11829392. DOI: 10.1186/s12943-025-02226-9.


Dendritic cell maturation in cancer.

Moon C, Belabed M, Park M, Mattiuz R, Puleston D, Merad M Nat Rev Cancer. 2025; .

PMID: 39920276 DOI: 10.1038/s41568-024-00787-3.


Disrupting EDEM3-induced M2-like macrophage trafficking by glucose restriction overcomes resistance to PD-1/PD-L1 blockade.

Peng S, Wu M, Yan Q, Xu G, Xie Y, Tang G Clin Transl Med. 2025; 15(1):e70161.

PMID: 39754316 PMC: 11702414. DOI: 10.1002/ctm2.70161.


Tumor microenvironment and immunotherapy for triple-negative breast cancer.

Guo Z, Zhu Z, Lin X, Wang S, Wen Y, Wang L Biomark Res. 2024; 12(1):166.

PMID: 39741315 PMC: 11689763. DOI: 10.1186/s40364-024-00714-6.


CD8 T cell exhaustion in the tumor microenvironment of breast cancer.

Xie H, Xi X, Lei T, Liu H, Xia Z Front Immunol. 2024; 15:1507283.

PMID: 39717767 PMC: 11663851. DOI: 10.3389/fimmu.2024.1507283.


References
1.
Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M . Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest. Cancer Immunol Res. 2014; 3(1):26-36. DOI: 10.1158/2326-6066.CIR-14-0098. View

2.
Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

3.
Li H, van der Leun A, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi A . Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell. 2019; 176(4):775-789.e18. PMC: 7253294. DOI: 10.1016/j.cell.2018.11.043. View

4.
Adams S, Gatti-Mays M, Kalinsky K, Korde L, Sharon E, Amiri-Kordestani L . Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncol. 2019; 5(8):1205-1214. PMC: 8452050. DOI: 10.1001/jamaoncol.2018.7147. View

5.
Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K . Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2017; 19(1):40-50. DOI: 10.1016/S1470-2045(17)30904-X. View